Allogene Therapeutics Inc (ALLO, Financial) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $0.01 million, and the earnings are expected to come in at -$0.33 per share. The full year 2024's revenue is expected to be $0.06 million, and the earnings are expected to be -$1.40 per share. More detailed estimate data can be found on the Forecast page.
Allogene Therapeutics Inc (ALLO, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Allogene Therapeutics Inc (ALLO) for the full year 2024 have increased from $0.05 million to $0.06 million. However, the revenue estimates for 2025 have declined from $4.73 million to $4.12 million. Earnings estimates for the full year 2024 have improved from -$1.55 per share to -$1.40 per share, and for 2025, the estimates have increased from -$1.56 per share to -$1.47 per share.
Allogene Therapeutics Inc (ALLO, Financial) Reported History
In the previous quarter of March 31, 2024, Allogene Therapeutics Inc's (ALLO) actual revenue was $0.02 million, which beat analysts' revenue expectations of $0.01 million by 120%. Allogene Therapeutics Inc's (ALLO) actual earnings were -$0.35 per share, which met analysts' earnings expectations. After releasing the results, Allogene Therapeutics Inc (ALLO) was up by 2.07% in one day.
Allogene Therapeutics Inc (ALLO, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 12 analysts, the average target price for Allogene Therapeutics Inc (ALLO) is $9.51 with a high estimate of $14 and a low estimate of $3.50. The average target implies an upside of 218% from the current price of $2.99.
Based on GuruFocus estimates, the estimated GF Value for Allogene Therapeutics Inc (ALLO, Financial) in one year is $0, suggesting a downside of -100% from the current price of $2.99.
Based on the consensus recommendation from 17 brokerage firms, Allogene Therapeutics Inc's (ALLO, Financial) average brokerage recommendation is currently 1.9, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
